ClinicalTrials.gg
RecruitingNCT07635056Updated Aug 24, 2026

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

A Phase 2 interventional study of CIML-NK Cells in Neuroblastoma, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Year to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 469 studies in Neuroblastoma with a site in United States — 54 open to participants now, 103 under way, 4 of them phase 3. Neuroblastoma · United States.

Planned enrollment
253rd of 379
20 · median 31
Started
2026
with 9 others
Phase 2
129 of 469
14 open now
Primary completion
2031-06
later than 90 of 100 live
Registered
467th of 469
by date

Among the 469 studies in Neuroblastoma with a site in United States, this one is the 253rd largest by planned enrollment of the 379 interventional ones that give a count, is one of 10 that started in 2026, is one of 129 in phase 2, reaches primary completion later than 90 of the 100 other live ones, and was the 467th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

54 of the 469 studies in Neuroblastoma with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 469 studies in Neuroblastoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.

03

Conditions studied

  • Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
1 Year to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1-39 years at the time of study enrollment
  • With diagnosis of neuroblastoma with histologic verification
  • Classified as high-risk neuroblastoma as defined by Children's Oncology Group (COG) risk classification, including patients initially classified as low or intermediate risk at diagnosis with subsequent reclassification as high-risk disease
  • With disease, including at least one of the following:

    1. Recurrent disease at any time after completion of frontline therapy
    2. Progressive disease at any time following standard induction therapy
    3. Primary resistant or refractory disease defined by failure to achieve a complete response by International Neuroblastoma Response Criteria (INRC) after at least four cycles of standard, multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol
  • Patients must have evaluable disease documented within four weeks of study enrollment. Evaluable disease must include at least one of the following:

    1. Measurable tumor (>10 mm in at least one dimension) on MRI or CT scan that is either MIBG, FDG or 68Ga-DOTATATE avid
    2. One or more MIBG, FDG, or 68Ga-DOTATATE avid bone lesion
    3. Microscopic marrow based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and at the time of study enrollment.
  • With performance level of >50% on Lansky (\<16 years) or (>16 years) scales. Patients who are wheelchair bound due to paralysis will be considered ambulatory when assessing their performance score.
  • Adequate baseline cardiac and pulmonary function including a (LVEF) >50% by echocardiogram and pulse oximetry >92% on room air documented within four weeks of study enrollment.
  • Adequate baseline hematologic function: peripheral (ANC) ≥500/µL, with no receipt of long-acting myeloid growth factors within 14 days or short-acting myeloid growth factors within 7 days of study entry, and a count ≥50,000/µL, with patients required to be transfusion independent for at least 7 days, unless cytopenias are related to marrow metastasis as defined above.
  • With available haploidentical related donors.

Exclusion criteria

Exclusion Criteria:

  • Infectious disease: Active, uncontrolled infection or received a within 30 days prior to study enrollment.
  • Cardiac function: \<50% by echocardiogram, serious uncontrolled cardiac arrhythmias, or history of myocarditis or congestive heart failure ( Functional Classification III or IV)
  • Pulmonary function: Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring systemic treatment.
  • Renal function: Glomerular Function Rate () \<50 mL/min/1.73 m2 as measured by cystatin C or NM GFR
  • Hepatic function: Total >5 mg/dL, and ALT >10 times the
  • Concomitant medications: receiving >0.5 mg/kg prednisone equivalent daily
  • Receipt of any concomitant treatments within 30 days at the time of the infusion of the IP. These investigational treatments include drugs, biologics, or devices that are still under investigation in clinical trials or research settings. The use of such agents may confound study results or pose additional safety risks
  • Known allergy or reaction to IL-2 injections
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cytokine-Induced Memory-Like Natural Killer (CIML-NK) Cells

    The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product.

    Biological: CIML-NK Cells

Interventions

  • BiologicalCIML-NK Cells

    The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of: * Cytokine-Induced Memory-Like NK cells (CIML-NK cells) * Human Serum Albumin * Plasmalyte The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested.

06

What researchers measure

Primary outcomes

  1. Infusional Toxicity

    Number of subjects who receive an infusion of cytokine-induced memory-like natural killer cells (CIML-NK cells) without grade 3-4 infusional toxicity events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 divided by the number of patients enrolled.

    Time frame: 30 days

Secondary outcomes

  1. Clinical Response or Disease Stability to Study Treatment

    Number of subjects who demonstrate clinical response to study treatment assessed by modified International Neuroblastoma Response Criteria.

    Time frame: end of cycle 2 (approximately study day 56)

Other outcomes

  1. Persistence of Cytokine-induced Memory-like Natural Killer (CIML-NK) cells in the Recipient's Peripheral Blood

    Number of subjects who have persistence of CIML-NK cells in the recipient's peripheral blood, assessed via short tandem repeats assays

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2031, 54 months later.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 54 months is below that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 9, 2026
StartEst.
Dec 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07635056
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Aug 24, 2026

Study contacts

Caitlin Cottrell, BSN, RN
Contact
Caitlin.cottrell@cchmc.org
513-803-7039
Christopher Dandoy, MD, MS
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion